Pfizer's ($PFE) new CEO Ian Read might want to trim certain business units to morph the drug giant into a pure pharmaceutical research company like Eli Lilly ($LLY), Forbes' Matthew Herper writes today, citing recent note from Bernstein Pharmaceuticals analyst Tim Anderson. The analyst wrote that the strategy could mean transactions that would divest businesses that account for 40 percent or $32 billion of Pfizer's $67 billion in annual sales, according to Herper's piece. Story